Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Cannata

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
European Heart Journal|November 28, 2025
Vericiguat in heart failure with reduced ejection fraction: being confident in the face of uncertaintyAntonio Cannata, Milton Packer
JACC. Cardiooncology|October 31, 2024
Preventing Cancer Therapy-Related Cardiotoxicity: Should We be PROACTive or Reactive?Antonio Cannata, Theresa McDonagh
JACC. Asia|June 16, 2023
Importance of Adding Quality of Life to Years of Life in Patients With Heart FailureAntonio Cannata, Gianluigi Savarese
JACC. Heart Failure|August 30, 2025
Inflammation in HFrEF: From Observation to Intervention?Antonio Cannata, Daniel I Bromage
European Journal of Heart Failure|March 2, 2026
Response to the letter by Mapelli et alDaniel I Bromage, Antonio Cannata
The New England Journal of Medicine|January 8, 2025
Heart Failure with Preserved Ejection FractionAntonio Cannata, Theresa A McDonagh
Future Cardiology|April 9, 2025
Current and future landscape of heart failure management: understanding the present, unraveling the futureCristina Madaudo, Daniel Bromage, Antonio Cannata
JACC. Basic to Translational Science|April 1, 2024
Myocardial Matrix Hydrogels for Cardiac Repair: The Devil Is in the DetailsMarika Fava, Antonio Cannata, Javier Barallobre-Barreiro
European Heart Journal. Quality of Care & Clinical Outcomes|May 8, 2020
Cardiology after COVID-19: Quo Vademus?Antonio Cannata, Daniel I Bromage, Theresa McDonagh
Journal of Cardiovascular Pharmacology|January 2, 2025
Interleukin-1 Blockade in Myocardial Infarction and Its Efficacy in Patients With Complex Coronary Artery Disease: Another Brick in the WallMatthew Sadler, Cristina Madaudo, Antonio Cannata, et al.
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
European Heart Journal|November 28, 2025
Vericiguat in heart failure with reduced ejection fraction: being confident in the face of uncertaintyAntonio Cannata, Milton Packer
JACC. Cardiooncology|October 31, 2024
Preventing Cancer Therapy-Related Cardiotoxicity: Should We be PROACTive or Reactive?Antonio Cannata, Theresa McDonagh
JACC. Asia|June 16, 2023
Importance of Adding Quality of Life to Years of Life in Patients With Heart FailureAntonio Cannata, Gianluigi Savarese
JACC. Heart Failure|August 30, 2025
Inflammation in HFrEF: From Observation to Intervention?Antonio Cannata, Daniel I Bromage
European Journal of Heart Failure|March 2, 2026
Response to the letter by Mapelli et alDaniel I Bromage, Antonio Cannata
The New England Journal of Medicine|January 8, 2025
Heart Failure with Preserved Ejection FractionAntonio Cannata, Theresa A McDonagh
Future Cardiology|April 9, 2025
Current and future landscape of heart failure management: understanding the present, unraveling the futureCristina Madaudo, Daniel Bromage, Antonio Cannata
JACC. Basic to Translational Science|April 1, 2024
Myocardial Matrix Hydrogels for Cardiac Repair: The Devil Is in the DetailsMarika Fava, Antonio Cannata, Javier Barallobre-Barreiro
European Heart Journal. Quality of Care & Clinical Outcomes|May 8, 2020
Cardiology after COVID-19: Quo Vademus?Antonio Cannata, Daniel I Bromage, Theresa McDonagh
Journal of Cardiovascular Pharmacology|January 2, 2025
Interleukin-1 Blockade in Myocardial Infarction and Its Efficacy in Patients With Complex Coronary Artery Disease: Another Brick in the WallMatthew Sadler, Cristina Madaudo, Antonio Cannata, et al.
Pageof 10